Market News / Story
Larimar Therapeutics, Inc. Stock 12‑Month Price Target Raised to $14.89, Implies 451% Upside
·
According to estimates from 9 analysts, Larimar Therapeutics, Inc. stock's average price target has risen from $14.4 to $14.89, with forecasts ranging from $5 to $26 per share Based on the Oct. 8 closing price, the updated target implies approximately 451% potential upside Consensus rating remains at “Buy” across 10 covering analysts, with 10 Buys, 0 Holds and 0 Sells Explore more price target data and ratings for Larimar Therapeutics, Inc. on the Forecasts tab , and…